Update on NSAIDs Related Peptic Ulcers.
- Author:
Dong Wook CHOI
1
;
Sung Chul PARK
;
Hoon Jai CHUN
Author Information
1. Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea.
- Publication Type:Review
- Keywords:
Non-steroidal anti-inflammatory drugs;
Peptic ulcer;
Treatment;
Prevention
- MeSH:
Adrenal Cortex Hormones;
Anti-Inflammatory Agents, Non-Steroidal*;
Anticoagulants;
Aspirin;
Cardiovascular Diseases;
Helicobacter pylori;
Humans;
Misoprostol;
Peptic Ulcer*;
Prostaglandin-Endoperoxide Synthases;
Proton Pump Inhibitors;
Risk Factors
- From:Korean Journal of Medicine
2014;86(6):664-672
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Nonsteroidal anti-inflammatory drugs (NSAIDs) have analgesic, antipyretic, and anti-inflammatory properties and are widely used for treating musculoskeletal and cardiovascular diseases. Notwithstanding these therapeutic efficacies, gastrointestinal toxicity is the major health problem associated with NSAID use. NSAID-related peptic ulcers are a well-known complication due to direct mucosal injury and cyclooxygenase inhibition. Risk factors for NSAID-related peptic ulcers include a prior history of peptic ulcer; age > 65 years; high-dose NSAID therapy; and concurrent use of aspirin (including low dose), corticosteroids, or anticoagulants. In addition, Helicobacter pylori infection is an independent risk factor; therefore, eradication therapy is recommended in high-risk patients using NSAIDs. Currently, misoprostol, H2-receptor antagonists, proton pump inhibitors, and COX-2 selective inhibitors are used to prevent and treat NSAID-related peptic ulcers. Further, strategic approaches are required through appropriate NSAID use and risk factor stratification to prevent NSAID-related peptic ulcers and associated complications.
